Abstract
Original language | English |
---|---|
Pages (from-to) | S2-S12 |
Journal | Clinical Cardiology |
Volume | 45 |
Issue number | S1 |
DOIs | |
Publication status | Published - 2022 |
Keywords
- clinical syndrome
- HFpEF
- HFrEF
- NT-proBNP
- stakeholders
- symptoms and signs
- universal definition of heart failure
Fingerprint
Dive into the research topics of 'Clinical implications of the universal definition for the prevention and treatment of heart failure: Clinical Cardiology'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Clinical implications of the universal definition for the prevention and treatment of heart failure : Clinical Cardiology. / Chandramouli, C.; Stewart, S.; Almahmeed, W. et al.
In: Clinical Cardiology, Vol. 45, No. S1, 2022, p. S2-S12.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Clinical implications of the universal definition for the prevention and treatment of heart failure
T2 - Clinical Cardiology
AU - Chandramouli, C.
AU - Stewart, S.
AU - Almahmeed, W.
AU - Lam, C.S.P.
N1 - Cited By :1 Export Date: 12 July 2022 CODEN: CLCAD Correspondence Address: Lam, C.S.P.; National Heart Centre SingaporeSingapore; email: carolyn.lam@duke-nus.edu.sg Funding details: Amgen Funding details: AstraZeneca Funding details: Bayer Funding details: Merck Funding details: Novartis Funding details: Roche Funding details: Boehringer Ingelheim Funding details: Boston Scientific Corporation, BSC Funding details: Cytokinetics, CYTK Funding details: National Medical Research Council, NMRC Funding details: Novo Nordisk Funding text 1: Chanchal Chandramouli reports philanthropic research support from Lee Foundation Singapore and has received consultancy or speaker fees from Us2.ai, Boehringer Ingelheim, and Sanofi Aventis. Simon Stewart is supported by the NHMRC of Australia (GNT 1135894); has received speaking fees or honoraria from Edwards Lifesciences and Novartis; has received consultancy fees from Edwards Lifesciences (UK and Australia) and Novartis Australia; reports participation on a data safety monitoring board or advisory board at Edwards Lifesciences. Carolyn Su Ping Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific and Roche Diagnostics; has served as a consultant or on the Advisory Board/Steering Committee/Executive Committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., Us2.ai, Janssen Research & Development LLC, Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, and WebMD Global LLC; and serves as cofounder and nonexecutive director of Us2.ai. Wael Almahmeed has nothing to declare. References: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) Lancet, 392, pp. 1789-1858; Heidenreich, P.A., Albert, N.M., Allen, L.A., Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association (2013) Circulation, 6, pp. 606-619; Fonarow, G.C., Albert, N.M., Curtis, A.B., Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) (2010) Circulation, 122, pp. 585-596; Greene, S.J., Butler, J., Albert, N.M., Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry (2018) J Am Coll Cardiol, 72, pp. 351-366; Vogel, B., Acevedo, M., Appelman, Y., The Lancet women and cardiovascular disease commission: reducing the global burden by 2030 (2021) Lancet, 397, pp. 2385-2438; Bozkurt, B., Coats, A.J., Tsutsui, H., Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure (2021) J Card Fail, 23, pp. 352-380; Davis, R.C., Hobbs, F.D., Lip, G.Y., ABC of heart failure. History and epidemiology (2000) BMJ, 320, pp. 39-42; Heidenreich, P.A., Bozkurt, B., Aguilar, D., 2022 HA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines (2022) Circulation, 145 (18), pp. e876-e894; McDonagh, T.A., Metra, M., Adamo, M., 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2021) Eur Heart J, 42, pp. 3599-3726; Tsutsui, H., Isobe, M., Ito, H., JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure—Digest Version (2019) Circulation, 83, pp. 2084-2184; Yancy, C.W., Jessup, M., Bozkurt, B., ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America (2017) Circulation, 2017 (136), pp. e137-e161; Yancy, C.W., Jessup, M., Bozkurt, B., ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines (2013) Circulation, 2013 (128), pp. e240-e327; Thygesen, K., Alpert, J.S., Jaffe, A.S., Fourth universal definition of myocardial infarction (2018) (2018) J Am Coll Cardiol, 72, pp. 2231-2264; Santos, G.C., Liljeroos, M., Dwyer, A.A., Symptom perception in heart failure: a scoping review on definition, factors and instruments (2020) Eur J Cardiovasc Nurs, 19, pp. 100-117; Stewart, S., Stewart, A.R., Waite, L., Beilby, J., Out with the old and in with the new: primary care management of heart failure with preserved ejection fraction (2022) Card Fail Rev, 8; Hicks, K.A., Mahaffey, K.W., Mehran, R., 2017 cardiovascular and stroke endpoint definitions for clinical trials (2018) Circulation, 2018 (137), pp. 961-972; The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis (2012) Eur Heart J, 33, pp. 1750-1757; Solomon, S.D., Vaduganathan, M., L Claggett, B., Sacubitril/valsartan across the spectrum of ejection fraction in heart failure (2020) Circulation, 141, pp. 352-361; Lund, L.H., Claggett, B., Liu, J., Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum (2018) Eur J Heart Fail, 20, pp. 1230-1239; Cleland, J.G., Bunting, K.V., Flather, M.D., Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials (2018) Eur Heart J, 39, pp. 26-35; Strange, G., Playford, D., Scalia, G.M., Change in ejection fraction and long-term mortality in adults referred for echocardiography (2021) Eur J Heart Fail, 23, pp. 555-563; Stewart, S., Playford, D., Scalia, G.M., Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men (2021) Eur J Heart Fail, 23, pp. 406-416; Piepoli, M.F., Adamo, M., Barison, A., Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology (2022) Eur J Heart Fail, 24, pp. 143-168; Mueller, C., McDonald, K., de Boer, R.A., Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations (2019) Eur J Heart Fail, 21, pp. 715-731; Aimo, A., Januzzi, J.L., Jr., Vergaro, G., Revisiting the obesity paradox in heart failure: per cent body fat as predictor of biomarkers and outcome (2019) Eur J Prev Cardiol, 26, pp. 1751-1759; Chandramouli, C., Tay, W.T., Bamadhaj, N.S., Association of obesity with heart failure outcomes in 11 Asian regions: a cohort study (2019) PLoS Med, 16; Buckley, L.F., Canada, J.M., Del Buono, M.G., Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction (2018) ESC heart failure, 5, pp. 372-378; Parcha, V., Patel, N., Kalra, R., Suri, S.S., Arora, G., Wang, T.J., and Arora P. Obesity and serial NT-proBNP levels in guided medical therapy for heart failure with reduced ejection fraction: insights from the GUIDE-IT Trial (2021) J Am Heart Assoc, 10; Anand, I.S., Claggett, B., Liu, J., Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT Trial (2017) JACC Heart Fail, 5, pp. 241-252; Vergaro, G., Gentile, F., Meems, L.M.G., NT-proBNP for risk prediction in heart failure: identification of optimal cutoffs across body mass index categories (2021) JACC Heart Fail, 9, pp. 653-663; Abramov, D., Kittleson, M.M., The universal definition of heart failure: strengths and opportunities (2021) J Card Fail, 27, pp. 622-624; Deferrari, G., Cipriani, A., La Porta, E., Renal dysfunction in cardiovascular diseases and its consequences (2021) J Nephrol, 34, pp. 137-153; Greene, F.L., Balch, C.M., Fleming, I.D., (2002) AJCC cancer staging handbook: TNM classification of malignant tumors, , Springer Science & Business Media; Tsao, C.W., Aday, A.W., Almarzooq, Z.I., Heart disease and stroke statistics—2022 update: a report from the American Heart Association (2022) Circulation, 145, pp. e153-e639; Kovell, L.C., Juraschek, S.P., Russell, S.D., Stage A heart failure is not adequately recognized in US adults: analysis of the National Health and Nutrition Examination Surveys, 2007–2010 (2015) PLoS One, 10; Kaspar, M., Fette, G., Güder, G., Underestimated prevalence of heart failure in hospital inpatients: a comparison of ICD codes and discharge letter information (2018) Clin Res Cardiol, 107, pp. 778-787; Park, J.J., Mebazaa, A., Hwang, I.C., Park, J.B., Park, J.H., Cho, G.Y., Phenotyping heart failure according to the longitudinal ejection fraction change: myocardial strain, predictors, and outcomes (2020) J Am Heart Assoc, 9; Savarese, G., Vedin, O., D'Amario, D., Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure (2019) JACC Heart Fail, 7, pp. 306-317; Hollenberg, S.M., Warner Stevenson, L., Ahmad, T., ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: a report of the American College of Cardiology Solution Set Oversight Committee (2019) J Am Coll Cardiol, 2019 (74), pp. 1966-2011; Halliday, B.P., Wassall, R., Lota, A.S., Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial (2019) Lancet, 393, pp. 61-73; Coller, J.M., Gong, F.F., McGrady, M., Risk factors for asymptomatic echocardiographic abnormalities that predict symptomatic heart failure (2022) ESC Heart Fail, 9, pp. 196-212; Krist, A.H., Davidson, K.W., Mangione, C.M., Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force Recommendation Statement (2020) JAMA, 324, pp. 2069-2075; Van Horn, L., Carson, J.A., Appel, L.J., Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) Guidelines: a scientific statement from the American Heart Association (2016) Circulation, 134, pp. e505-e529; Wickman, B.E., Enkhmaa, B., Ridberg, R., Dietary management of heart failure: DASH diet and precision nutrition perspectives (2021) Nutrients, 13, p. 13; Ledwidge, M., Gallagher, J., Conlon, C., Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF Randomized Trial (2013) JAMA, 310, pp. 66-74; Stewart, S., Chan, Y.K., Wong, C., Impact of a nurse-led home and clinic-based secondary prevention programme to prevent progressive cardiac dysfunction in high-risk individuals: the Nurse-led Intervention for Less Chronic Heart Failure (NIL-CHF) randomized controlled study (2015) Eur J Heart Fail, 17, pp. 620-630; Playford, D., Strange, G., Celermajer, D.S., Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA) (2021) Eur Heart J Cardiovasc Imaging, 22, pp. 505-515; Shah, A.M., Shah, S.J., Anand, I.S., Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an Aldosterone Antagonist trial (2014) Circ Heart Fail, 7, pp. 104-115; Zile, M.R., Gottdiener, J.S., Hetzel, S.J., Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction (2011) Circulation, 124, pp. 2491-501.; Vaidya, G.N., Abramov, D., Echocardiographic evaluation of diastolic function is of limited value in the diagnosis and management of HFpEF (2018) J Card Fail, 24, pp. 392-396; Natriuretic Peptides Studies, C., Willeit, P., Kaptoge, S., Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis (2016) Lancet Diabetes Endocrinol, 4, pp. 840-849; Cleland, J.G.F., Pfeffer, M.A., Clark, A.L., The struggle towards a Universal Definition of Heart Failure—how to proceed? (2021) Eur Heart J, 42, pp. 2331-2343; Cediel, G., Codina, P., Spitaleri, G., Gender-related differences in heart failure biomarkers (2020) Front Cardiovasc Med, 7; Gaggin, H.K., Dang, P.V., Do, L.D., Reference interval evaluation of high-sensitivity troponin T and N-terminal B-type natriuretic peptide in Vietnam and the US: the North South East West Trial (2014) Clin Chem, 60, pp. 758-764; Gupta, D.K., Walford, G.A., Ma, Y., Jarolim, P., Wang, T.J., Racial/ethnic differences in circulating natriuretic peptide levels: the Diabetes Prevention Program (2020) PLoS One, 15; Shi, X., Xu, G., Xia, T., Song, Y., Lin, Q., N-terminal-pro-B-type natriuretic peptide (NT-proBNP): reference range for Chinese apparently healthy people and clinical performance in Chinese elderly patients with heart failure (2005) Clin Chim Acta, 360, pp. 122-127; Galderisi, M., Cosyns, B., Edvardsen, T., Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging (2017) Eur Heart J Cardiovasc Imaging, 18, pp. 1301-1310; Lang, R.M., Badano, L.P., Mor-Avi, V., Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging (2015) Eur Heart J Cardiovasc Imaging, 16, pp. 233-270; McGowan, J.H., Cleland, J.G.F., Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods (2003) Am Heart J, 146, pp. 388-397; Savarese, G., Stolfo, D., Sinagra, G., Lund, L.H., Heart failure with mid-range or mildly reduced ejection fraction (2022) Nat Rev Cardiol, 19, pp. 100-116; Lam, C.S., Solomon, S.D., Fussing over the middle child: heart failure with mid-range ejection fraction (2017) Circulation, 135, pp. 1279-1280; Haji, K., Marwick, T.H., Stewart, S., Incremental value of global longitudinal strain in the long-term prediction of heart failure among patients with coronary artery disease (2022) J Am Soc Echocardiogr, 35, pp. 187-195; Tromp, J., Seekings, P.J., Hung, C.L., Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study (2022) Lancet Digit Health, 4, pp. e46-e54; Albert, N.M., Universal definition and classification of heart failure: new clarity brings new clinical implications for health care professionals and the need for new research (2021) J Card Fail, 27, pp. 744-746; Hancock, H.C., Close, H., Mason, J.M., High prevalence of undetected heart failure in long-term care residents: findings from the Heart Failure in Care Homes (HFinCH) study (2013) Eur J Heart Fail, 15, pp. 158-165; Smeets, M., Vaes, B., Aertgeerts, B., Impact of an extended audit on identifying heart failure patients in general practice: baseline results of the OSCAR-HF pilot study (2020) ESC Heart Fail, 7, pp. 3950-3961; van Riet, E.E., Hoes, A.W., Limburg, A., Landman, M.A., van der Hoeven, H., Rutten, F.H., Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion (2014) Eur J Heart Fail, 16, pp. 772-777; Bottle, A., Kim, D., Aylin, P., Cowie, M.R., Majeed, A., Hayhoe, B., Routes to diagnosis of heart failure: observational study using linked data in England (2018) Heart, 104, pp. 600-605; Roalfe, A.K., Taylor, C.J., Kelder, J.C., Hoes, A.W., Hobbs, F.D.R., Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies (2021) ESC Heart Fail, 8, pp. 2193-2201; Storrow, A.B., Jenkins, C.A., Self, W.H., The burden of acute heart failure on U.S. emergency departments (2014) JACC Heart Fail, 2, pp. 269-277; Maggioni, A.P., Dahlström, U., Filippatos, G., EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot) (2013) Eur J Heart Fail, 15, pp. 808-817; Riley, J.P., Masters, J., Practical multidisciplinary approaches to heart failure management for improved patient outcome (2016) Eur Heart J Suppl, 18, pp. G43-G52; Blecker, S., Katz, S.D., Horwitz, L.I., Comparison of approaches for heart failure case identification from electronic health record data (2016) JAMA Cardiol, 1, pp. 1014-1020; Slavici, T., Avram, C., Mnerie, G.V., Economic efficiency of primary care for CVD prevention and treatment in Eastern European countries (2013) BMC Health Serv Res, 13, p. 75; Ow Yong, L.M., Koe, L.W.P., War on diabetes in Singapore: a policy analysis (2021) Health Res Policy Syst, 19, p. 15; Li, P., McElligott, S., Bergquist, H., Schwartz, J.S., Doshi, J.A., Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia (2012) Ann Intern Med, 156, pp. 776-784
PY - 2022
Y1 - 2022
N2 - The diagnosis of heart failure (HF) primarily relies on signs and symptoms that are neither sensitive nor specific. This impedes timely diagnosis and delays effective therapies or interventions, despite the availability of several evidence-based treatments for HF. Through monumental collaborative efforts from representatives of HF societies worldwide, the universal definition of HF was published in 2021, to provide the necessary standardized framework required for clinical management, clinical trials, and research. This review elaborates the key concepts of the new universal definition of HF, highlighting the key merits and potential avenues, which can be nuanced further in future iterations. We also discuss the key implications of the universal definition document from the perspectives of various stakeholders within the healthcare framework, including patients, care providers, system/payers and policymakers. © 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
AB - The diagnosis of heart failure (HF) primarily relies on signs and symptoms that are neither sensitive nor specific. This impedes timely diagnosis and delays effective therapies or interventions, despite the availability of several evidence-based treatments for HF. Through monumental collaborative efforts from representatives of HF societies worldwide, the universal definition of HF was published in 2021, to provide the necessary standardized framework required for clinical management, clinical trials, and research. This review elaborates the key concepts of the new universal definition of HF, highlighting the key merits and potential avenues, which can be nuanced further in future iterations. We also discuss the key implications of the universal definition document from the perspectives of various stakeholders within the healthcare framework, including patients, care providers, system/payers and policymakers. © 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
KW - clinical syndrome
KW - HFpEF
KW - HFrEF
KW - NT-proBNP
KW - stakeholders
KW - symptoms and signs
KW - universal definition of heart failure
U2 - 10.1002/clc.23842
DO - 10.1002/clc.23842
M3 - Article
VL - 45
SP - S2-S12
JO - Clinical Cardiology
JF - Clinical Cardiology
SN - 0160-9289
IS - S1
ER -